mutation class

Gene Expression

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

256 sites for NCT03952585

CDKN2A Overexpression, +1 more biomarker

Oropharyngeal Squamous Cell Carcinoma

nivolumab, +1 more drug

immunotherapy, +1 more type

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

403 sites for NCT03811015

CDKN2A Overexpression, +1 more biomarker

Oropharyngeal Carcinoma

cisplatin, +2 more drugs

chemotherapy, +2 more types

Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca

1 site for NCT04988074

CDKN2A Overexpression, +1 more biomarker

Head and Neck Squamous Cell Carcinoma

cemiplimab

immunotherapy

Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

27 sites for NCT04646005

CDKN2A Overexpression, +1 more biomarker

Cervical Squamous Cell Carcinoma

cemiplimab, +1 more drug

immunotherapy

A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

28 sites for NCT04398524

CDKN2A Overexpression, +1 more biomarker

Oropharyngeal Squamous Cell Carcinoma

cemiplimab, +1 more drug

immunotherapy

Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma

1 site for NCT04852328

CDKN2A Overexpression, +1 more biomarker

Oropharyngeal Squamous Cell Carcinoma

cisplatin, +3 more drugs

chemotherapy, +3 more types